A5025287776- Thyroid Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Cancer, Stress, Anesthesia, and Immune Response
- Effects of Radiation Exposure
- Radiation Dose and Imaging
- Cancer Immunotherapy and Biomarkers
Shanxi Medical University
2022-2023
First Hospital of Shanxi Medical University
2022-2023
The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.This multicenter, double-blind, placebo-controlled, III enrolled 191 RAIR-DTC randomized a ratio 2:1 (300 mg twice daily,...
Differentiated thyroid cancer is the most frequently diagnosed endocrine tumor. While differentiated cancers often respond to initial treatment, little known about differences in circulating immune cells amongst patients who differently. A prospective study of 39 with was conducted. Serum thyroglobulin levels and immunological functions were tested before after radioactive iodine treatment (RAIT). Efficacy assessments performed 6 12 months treatment. Most showed an excellent response Before...
<div>Abstract<p>Purpose: The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumour activity safety RAIR-DTC patients. Patients Methods: This multicenter, double-blind, placebo-controlled, III...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
With the rapid development of nuclear medicine, number medical staff has increased a lot in past few years China. Close-range operations, such as preparation and injections radiopharmaceuticals, are usually carried out medicine department. And use unsealed radionuclides may also create internal exposure risk. So, occupational is main issue health management In this paper, level requirements for radiation protection introduced to provide references related work that radiological technical...
<div>AbstractPurpose:<p>The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.</p>Patients Methods:<p>This multicenter, double-blind,...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>Abstract<p>Purpose: The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumour activity safety RAIR-DTC patients. Patients Methods: This multicenter, double-blind, placebo-controlled, III...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>AbstractPurpose:<p>The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.</p>Patients Methods:<p>This multicenter, double-blind,...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
The effects of total thyroidectomy or radioactive iodine therapy on immune activation and suppression the tumor microenvironment remain unknown. We aimed to investigate these treatments function in patients with differentiated thyroid carcinoma (DTC). Our cohort included 45 DTC treated (RAIT). Immune tests were performed by flow cytometry at 0, 30, 90 days post-RAIT. Both percentage absolute number circulating regulatory T cells significantly lower postoperative compared healthy controls....
Abstract Background No available treatment existed in Chinese patients with progressive radioactive iodine–refractory differentiated thyroid cancer (RAIR-DTC) terms of both affordability and safety upon the initiation DIRECTION study. Donafenib is an oral tyrosine kinase inhibitor (TKI) superior efficacy over sorafenib hepatocellular carcinoma (HCC) phase III This study aimed to evaluate its antitumour activity RAIR-DTC patients. Methods The sequential II/III design as a whole protocol was...